{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T15:32:06Z","timestamp":1784129526618,"version":"3.55.0"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T00:00:00Z","timestamp":1750204800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>We report herein the case of a patient diagnosed with high-risk neuroblastoma (HR-NB), treated with naxitamab following suboptimal response to induction chemotherapy, becoming the first patient to receive this therapy at the National Institute of Pediatrics (INP) in Mexico. We discuss the clinical course, therapeutic approach, response to treatment, adverse events, and fatal outcome, focusing on the implications of immunotherapy access in low- and middle-income countries (LMIC).<\/jats:p><\/jats:sec><jats:sec><jats:title>Case presentation<\/jats:title><jats:p>A 2-year-old male presented with a 3-month history of a left front-temporal mass and left-sided exophthalmos. Magnetic resonance imaging (MRI) revealed a poorly defined retroperitoneal and paravertebral mass, and a destructive cranial lesion involving the sphenoid wing and the orbit. PET-CT and MIBG scans confirmed widespread metastatic disease in bone, orbit, and intracranial structures, consistent with stage 4 neuroblastoma. Histopathology of a cranial biopsy confirmed poorly differentiated neuroblastoma. The patient was classified as high-risk based on age and metastatic disease, and underwent multimodal treatment including chemotherapy, partial tumor resection, radiotherapy, and anti-GD2 immunotherapy with naxitamab under protocol HITS-17-251. After five cycles, imaging showed complete response in cranial metastases. Adverse events during immunotherapy were mild (Grade I\u2013II), including erythema, pruritus, urticaria, and transient hypotension, all managed with antihistamines and IV fluids. However, one month after the final cycle, the patient developed sudden neurological deterioration with cerebral edema and hydrocephalus. Despite intensive care, he progressed to brain death, with neurotoxicity suspected as the cause.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>The primary objective of implementing novel immunotherapeutic strategies, in addition to improving event-free survival (EFS) and overall survival (OS) in patients diagnosed with high-risk neuroblastoma, is to reduce adverse effects and lower both short- and long-term mortality. It is worth noting that the current cost of anti-GD2 therapies available in Latin America is estimated to exceed $450,000 USD. In a country like Mexico, where the minimum daily wage is approximately $10 USD, access to these therapies remains unattainable for the majority of the population. Therefore, it is essential to highlight the importance and substantial clinical impact of immunotherapy on survival outcomes in patients with refractory neuroblastoma. This recognition should support advocacy for broader access to these therapies. Despite their high costs, the demonstrated benefits should outweigh the disadvantages, justifying efforts to make them accessible to all patient populations.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Future studies in LMICs including Mexico and Latin America, must focus on optimizing dosing strategies to minimize adverse effects and improve both survival outcomes and the quality of life for patients receiving immunotherapy.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2025.1520171","type":"journal-article","created":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T05:47:45Z","timestamp":1750225665000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["High-risk neuroblastoma in Mexico: from multimodal treatment to immunotherapy. Regarding the first case treated with naxitamab"],"prefix":"10.3389","volume":"15","author":[{"given":"Alberto","family":"Olaya Vargas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haydee","family":"Salazar-Rosales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcela","family":"Caballero-Palacios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nideshda","family":"Ram\u00edrez-Uribe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerardo","family":"L\u00f3pez-Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Morales-Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Cervantes-Delgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liliana","family":"Velasco Hidalgo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Araceli","family":"Castellanos-Toledo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roc\u00edo","family":"C\u00e1rdenas-Cardos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Niembro-Z\u00fa\u00f1iga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Rivera-Luna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Olaya-Nieto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas","family":"Ponce-Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime","family":"Shalkow-Klincovstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yadira","family":"Melchor-Vidal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"D\u00edaz-Machorro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.173337","article-title":"Single-cell analyses of metastatic bone marrow in human neuroblastoma reveals microenvironmental remodeling and metastatic signature","volume":"9","author":"Mei","year":"2024","journal-title":"JCI Insight"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1002\/ijc.v132.7","article-title":"Incidence of childhood cancer among Mexican children registered under a public medical insurance program","volume":"132","author":"Rivera-Luna","year":"2013","journal-title":"Int J Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.4648","article-title":"Advances in risk classification and treatment strategies for neuroblastoma","volume":"33","author":"Pinto","year":"2015","journal-title":"J Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.11101352","article-title":"Guidelines for imaging and staging of neuroblastic tumors: consensus report from the international neuroblastoma risk group project 1","volume":"261","author":"Brisse","year":"2011","journal-title":"Radiology"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6604640","article-title":"Treatment of localised resectable neuroblastoma. Results of the LNESG1 study by the SIOP Europe Neuroblastoma Group","volume":"99","author":"De Bernardi","year":"2008","journal-title":"Br J Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.25501","article-title":"SIOP-PODC adapted risk stratification and treatment guidelines: recommendations for neuroblastoma in low- and middle-income settings","volume":"62","author":"Parikh","year":"2015","journal-title":"Pediatr Blood Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.8-3-278","article-title":"Advances in the diagnosis and treatment of neuroblastoma","volume":"8","author":"Weinstein","year":"2003","journal-title":"Oncologist"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1080\/08880018.2017.1330375","article-title":"Neuroblastoma in children: Update on clinicopathologic and genetic prognostic factors","volume":"34","author":"Ahmed","year":"2017","journal-title":"Pediatr Hematol Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a014415","article-title":"Neuroblastoma and MYCN","volume":"3","author":"Huang","year":"2013","journal-title":"Cold Spring Harb Perspect Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"73","DOI":"10.2174\/1573396314666180129101627","article-title":"Biological and genetic features of neuroblastoma and their clinical importance","volume":"14","author":"Aygun","year":"2018","journal-title":"Curr Pediatr Rev"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/biology11101376","article-title":"Interplay: the essential role between INSM1 and N- Myc in aggressive neuroblastoma","volume":"11","author":"Chen","year":"2022","journal-title":"Biol (Basel)"},{"key":"B12","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/S1470-2045(13)70309-7","article-title":"Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): A randomised phase 3 trial","volume":"14","author":"Kreissman","year":"2013","journal-title":"Lancet Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"CD006301","DOI":"10.1002\/14651858.CD006301.pub4","article-title":"High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma","volume":"8","author":"Yal\u00e7in","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.v68.S2","article-title":"Neuroblastoma","volume":"68","author":"Chung","year":"2021","journal-title":"Pediatr Blood Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.11641","article-title":"Tandem transplant for high-risk neuroblastoma: next steps in the era of precision medicine","volume":"322","author":"Bagatell","year":"2019","journal-title":"JAMA"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0911123","article-title":"Anti- GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma","volume":"363","author":"Yu","year":"2010","journal-title":"N Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.febslet.2013.11.030","article-title":"Engineering anti-GD2 monoclonal antibodies for cancer immunotherapy","volume":"588","author":"Ahmed","year":"2013","journal-title":"FEBS Lett"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22116145","article-title":"Cancer-associated glycosphingolipids as tumor markers and targets for cancer immunotherapy","volume":"22","author":"Groux-Degroote","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-1824","article-title":"Pediatric cancers are infiltrated predominantly by macrophages and contain a paucity of dendritic cells: A major nosologic difference with adult tumors","volume":"12","author":"Vakkila","year":"2006","journal-title":"Clin Cancer Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.9558","article-title":"KIR3DL1 allelic polymorphism and HLA-B epitopes modulate response to anti-GD2 monoclonal antibody in patients with neuroblastoma","volume":"34","author":"Forlenza","year":"2016","journal-title":"J Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.4161\/onci.26860","article-title":"Harnessing the antitumor potential of macrophages for cancer immunotherapy","volume":"2","author":"Long","year":"2013","journal-title":"OncoImmunology"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/MPH.0000000000001607","article-title":"The role of surgery in high-risk neuroblastoma","volume":"42","author":"Ryan","year":"2020","journal-title":"J Pediatr Hematol Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.10022","article-title":"Poster 679: efficacy of naxitamab in patients with refractory\/relapse (R\/R) high-risk neuroblastoma (HR-NB) by bone\/bone marrow (BM) evaluation, potential sites of residual disease","volume":"39","author":"Kushner","year":"2021","journal-title":"J Clin Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.41.3807","article-title":"Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission","volume":"30","author":"Cheung","year":"2012","journal-title":"J Clin Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.10032","article-title":"Naxitamab-related adverse events within and across treatment cycles in patients with relapsed\/refractory (R\/R) high-risk neuroblastoma","volume":"42","author":"Mora","year":"2024","journal-title":"JCO"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.575009","article-title":"The Roleofautologousstem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy. Results of two consecutive studies","volume":"11","author":"Mora","year":"2020","journal-title":"Front Pharma- col"},{"key":"B27","article-title":"Dinotuximab en pacientes con neuroblastoma de alto riesgo","volume-title":"Documentos de Evaluaci\u00f3n de Tecnolog\u00edas Sanitarias","author":"Tapia L\u00f3pez","year":"2017"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15020648","article-title":"Naxitamab activity in neuroblastoma cells is enhanced by nanofenretinide and nanospermidine","volume":"15","author":"Galassi","year":"2023","journal-title":"Pharmaceutics"},{"key":"B29","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.3390\/cancers1509253","article-title":"Naxitamab combined with granulocyte-macrophage colony-stimulating factor as consolidation for high-risk neuroblastoma patients in first complete remission under compassionate use\u2014Updated outcome report","volume":"15","author":"Mora","year":"2023","journal-title":"Cancers"},{"key":"B30","doi-asserted-by":"publisher","first-page":"S1448","DOI":"10.1016\/j.annonc.2020.10.562","article-title":"Pivotal Trial 201 data on outpatient administration of naxitamab (Hu3F8), a humanized GD2 targeted immunotherapy for the treatment of refractory\/relapsed (R\/R) high-risk (HR) neuroblastoma (NB)","volume":"31","author":"Morgenstern","year":"2020","journal-title":"Ann Oncol"},{"key":"B31","unstructured":"Resoluci\u00f3n del H. Consejo de Representantes de la Comisi\u00f3n Nacional de los Salarios M\u00ednimos que fija los salarios m\u00ednimos generales y profesionales que habr\u00e1n de regir a partir del 1 de enero de 2025"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1520171\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T05:47:50Z","timestamp":1750225670000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1520171\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,18]]},"references-count":31,"alternative-id":["10.3389\/fonc.2025.1520171"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1520171","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,18]]},"article-number":"1520171"}}